Effect of beta-blockade on mortality in patients with heart failure: A meta-analysis of randomized clinical trials

Journal of the American College of Cardiology

Volumn 30, Issue 1, 1997, Pages 27-34

  Heidenreich, Paul A ^a,b   Lee, Tina T ^a   Massie, Barry M ^b  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; METOPROLOL; NEBIVOLOL;

ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESEARCH; DRUG SCREENING; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGED; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; MORTALITY; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS;

EID: 0030738423     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(97)00104-6     Document Type: Article

References (66)

1. Heart and Stroke Facts 1996 Statistical Supplement . 1996;15 American Heart Association, Chicago.
2. Mortality from congestive heart failure - United States, 1980-1990. MMWR. 43:1994;77-81.
3. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction results of the survival and ventricular enlargement trial . N Engl J Med. 327:1992;669-677.
4. Effects of enalapril on mortality in severe congestive heart failure results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) . N Engl J Med. 316:1987;1429-1435.
5. Cohn JN, Jonson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 325:1991;303-310.
6. Cohn J, Archibald D, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure results of a Veterans Administration Cooperative Study . N Engl J Med. 314:1986;1547-1552.
7. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 336:1997;525-533.
8. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure . N Engl J Med. 333:1995;77-82.
9. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet. 344:1994;493-498.
10. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe heart failure Prospective Randomized Amlodipine Survival Evaluation Study . N Engl J Med. 335:1996;1107-1114.
11. Feldman AM, Bristow MR, Parmley WW, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med. 329:1993;149-155.
12. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J. 37:1975;1022-1036.
13. Sackner-Bernstein JD, Mancini DM. Rationale for treatment of patients with chronic heart failure with adrenergic blockade. JAMA. 274:1995;1462-1467.
14. Anderson JL, Lutz JR, Gilbert EM, et al. A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol. 55:1985;471-475.
15. Bristow MR, O'Connell JB, Gilbert EM, et al. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation. 89:1994;1632-1642.
16. Eichhorn EJ, Heesch CM, Barnett JH, et al. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy a randomized, double-blind, placebo-controlled study . J Am Coll Cardiol. 24:1994;1310-1320.
17. Engelmeier RS, O'Connell JB, Walsh R, Rad N, Scanlon PJ, Gunnar RM. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy a double-blind, randomized, placebo-controlled trial . Circulation. 72:1985;536-546.
18. Fisher ML, Gottlieb SS, Plotnick GD, et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease a randomized trial . J Am Coll Cardiol. 23:1994;943-950.
19. Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation. 92:1995;1499-1506.
20. Metra M, Nodari S, Raccagni D, Garbellini M, Milan E, Cas LD. Relation between hemodynamic and functional capacity changes after chronic carvedilol therapy in patients with idiopathic dilated cardiomyopathy. [abstract]. Circulation. 92:(Suppl I):1995;I-393-I-394.
21. Zarembski D, Nolan P, Slack M, Lui C. Meta-analysis of the use of low-dose beta-adrenergic blocking therapy in idiopathic or ischemic dilated cardiomyopathy. Am J Cardiol. 77:1996;1247-1250.
22. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 334:1996;1349-1355.
23. Chatterjee K. Heart failure therapy in evolution. Circulation. 94:1996;2689-2693.
24. Petitti D. Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis. 1994;245 Oxford Univ Press, New York.
25. Mantel N. Chi-square tests with one degree of freedom extensions of the Mantel-Haenszel procedure . J Am Statistical Assoc. 58:1963;690-700.
26. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 22:1959;719-748.
27. Robins J, Greenland S, Breslow N. A general estimator for the variance of the Mantel-Haenszel odds ratio. Am J Epidemiol. 124:1986;719-723.
28. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 7:1986;177-188.
29. Fleiss J, Gross A. Meta-analysis in epidemiology, with special reference to studies of the association between exposure to environmental tobacco smoke and lung cancer a critique . J Clin Epidemiol. 44:1991;127-139.
30. Mantel N, Brown C, Byar D. Tests for homogeneity of effect in a epidemiologic investigation. Am J Epidemiol. 106:1977;125-129.
31. Hedges L, Olkin I. Statistical Methods for Meta-analysis. 1985;Academic Press, Orlando (FL).
32. Hedges L. Statistically analyzing effect sizes fixed effects models . Cooper LH. The Handbook of Research Synthesis. 1994;285-299 Russel Sage Foundation, New York.
33. A randomized trial of beta-blockade in heart failure the Cardiac Insufficiency Bisoprolol Study (CIBIS) . Circulation. 90:1994;1765-1773.
34. Carvedilol efficacy in severe heart failure. Data presented at the Cardiorenal Advisory Panel Meeting of the Food and Drug Administration, May 2, 1996. Protocol 239.
35. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 94:1996;2807-2816.
36. Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation. 94:1996;2800-2806.
37. Packer M, Colucci WS, Sackner BJ, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure the Prospective Randomized Evaluation of Carvedilol in Symptoms and Exercise (PRECISE) trial . Circulation. 94:1996;2793-2799.
38. Pollock SG, Lystash J, Tedesco C, Craddock G, Smucker ML. Usefulness of bucindolol in congestive heart failure. Am J Cardiol. 66:1990;603-607.
39. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet. 349:1997;375-380.
40. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure a double-blind randomized study . J Am Coll Cardiol. 25:1995;1225-1231.
41. Metra M, Nardi M, Giubbini R, Dei CL. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 24:1994;1678-1687.
42. Woodley SL, Gilbert EM, Anderson JL, et al. Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation. 84:1991;2426-2441.
43. Wisenbaugh T, Katz I, Davis J, et al. Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol. 21:1993;1094-1100.
44. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 342:1993;1441-1446.
45. Krum H, Gu A, Wilshire-Clement M, et al. Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure. Am Heart J. 131:1996;337-341.
46. Gilligan DM, Chan WL, Joshi J, et al. A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy. J Am Coll Cardiol. 21:1993;1672-1679.
47. Currie PJ, Kelly MJ, McKenzie A, et al. Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy. J Am Coll Cardiol. 3:1984;203-209.
48. Simarro E, Rodriguez MA, Bayon J, et al. The effect of gallopamil and propranolol in patients with ischemic cardiomyopathy and moderate depression of ventricular function. Rev Esp Cardiol. 48:1995;741-745.
49. Gilbert EM, Anderson JL, Deitchman D, et al. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy a double-blind, randomized study of bucindolo versus placebo . Am J Med. 88:1990;223-229.
50. Vedin A, Wikstrand J, Wilhelmsson C, Wallentin I. Left ventricular function and beta-blockade in chronic ischaemic heart failure double-blind, cross-over study of propranolol and penbutolol using non-invasive techniques . Br Heart J. 44:1980;101-107.
51. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol. 25:1995;1154-1161.
52. Shanes JG, Wolfkiel C, Ghali J, Dierenfeldt BJ, Kondos GT, Bauman JL. Acute hemodynamic effects of pindolol and propranolol in patients with dilated cardiomyopathy relevance of intrinsic sympathomimetic activity . Am Heart J. 116:1988;1268-1275.
53. Buchwald A, Unterberg C, van der Does R, Wiegand V. Acute hemodynamic effects of the vasodilator beta blocker carvedilol in heart failure. Z Kardiol. 79:1990;424-428.
54. Paolisso G, Gambardella A, Marrazzo G, et al. Metabolic and cardiovascular benefits deriving from beta-adrenergic blockade in chronic congestive heart failure. Am Heart J. 123:1992;103-110.
55. Hahn B, Strauer BE. The influence of beta-adrenoceptor blockade on left ventricular function. Br J Clin Pharmacol. 13:1982;305S-307S.
56. Andersson B, Hamm C, Persson S, et al. Improved exercise hemodynamic status in dilated cardiomyopathy after beta-adrenergic blockade treatment. J Am Coll Cardiol. 23:1994;1397-1404.
57. Regitz-Zagrosek V, Leuchs B, Krulls-Munch J, Fleck E. Angiotensin- converting enzyme inhibitors and beta-blockers in long-term treatment of dilated cardiomyopathy. Am Heart J. 129:1995;754-761.
58. Copie X, Pousset F, Lechat P, Jaillon P, Guize L, Le HJ. Effects of beta-blockade with bisoprolol on heart rate variability in advanced heart failure analysis of scatterplots of R-R intervals at selected heart rates . Am Heart J. 132:1996;369-375.
59. Pousset F, Copie X, Lechat P, et al. Effects of bisoprolol on heart rate variability in heart failure. Am J Cardiol. 77:1996;612-617.
60. Sanderson JE, Chan WW, Hung YT, et al. Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker . Br Heart J. 74:1995;502-507.
61. Cocco G, Alfiero R, Pouleur H. An evaluation of the safety of the beta-modulator cicloprolol in chronic heart failure. Clin Cardiol. 15:1992;38-42.
62. Effects of carvedilol, a vasodilator beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation. 92:1995;212-218.
63. Design of the Beta-blocker Evaluation of Survival Trial (BEST). Am J Cardiol. 75:1995;1220-1223.
64. Massie B, Fisher S, Deedwania P, Singh B, Fletcher R, Singh S. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. Circulation. 93:1996;2128-2134.
65. Armstrong PW, Moe GW. Medical advances in the treatment of congestive heart failure. Circulation. 88:1993;2941-2952.
66. Pitt B. The role of beta-adrenergic blocking agents in preventing sudden cardiac death. Circulation. 85:(Suppl I):1992;I-107-I-111.